By VETTAPHARMA reporter – Derek Roche: NATCO Pharma and its alliance partner Lupin reported that the U.S. Food and Drug Administration (FDA) approved NATCO’s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials. The approval expands the companies’ oncology portfolio in the United States and provides access to a product with estimated annual U.S. sales of $43.7 million.
Eribulin Mesylate Injection is the bioequivalent version of Halaven® (eribulin mesylate) Injection, marketed by Eisai. The approval allows NATCO and Lupin to commercialize a generic alternative for patients with specific advanced cancer indications.
The product is indicated for adults with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for metastatic disease. It is also approved for patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
The FDA approval was granted through the abbreviated new drug application pathway, which confirms bioequivalence to the reference listed drug. Eribulin Mesylate Injection, 1 mg/2 mL single-dose vials, was approved as therapeutically equivalent to Halaven® Injection.
Metastatic breast cancer remains one of the most common advanced malignancies worldwide, while liposarcoma is a rare soft tissue sarcoma with limited treatment options in advanced stages. Generic oncology products can play an important role in improving treatment accessibility and reducing healthcare costs for patients and healthcare systems.
The approval further strengthens NATCO’s strategy of focusing on limited-competition molecules in the U.S. market while leveraging its oncology expertise. For Lupin, the approval adds another oncology product to its U.S. portfolio through its alliance partnership with NATCO.
From a commercial perspective, the opportunity is supported by estimated annual U.S. sales of $43.7 million for the reference product Halaven® based on IQVIA MAT data for April 2026. The approval provides NATCO and Lupin an opportunity to compete in a specialized oncology segment while expanding their presence in the U.S. generics market.
Quick FAQs
1. What Is Eribulin Mesylate Injection?
Eribulin Mesylate Injection is a generic version of Halaven® (eribulin mesylate) Injection used to treat certain advanced cancers.
2. What Did the FDA Approve?
The FDA approved NATCO’s ANDA for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials.
3. What Is the Regulatory Submission?
The approval was granted through the ANDA pathway, which establishes bioequivalence to the reference listed drug Halaven®.
4. What Are the Approved Disease Conditions?
The product is indicated for metastatic breast cancer after at least two prior chemotherapy regimens and for unresectable or metastatic liposarcoma following a prior anthracycline-containing regimen.
5. What Are the Key Commercial Details?
The reference product Halaven® recorded estimated annual U.S. sales of $43.7 million based on IQVIA MAT April 2026 data.
6. Why Is This Approval Important?
The approval expands access to a generic oncology therapy while strengthening NATCO and Lupin’s presence in the U.S. oncology and specialty generics markets.
